132 related articles for article (PubMed ID: 19250825)
1. Discovery of [3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acids as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
Van Zandt MC; Doan B; Sawicki DR; Sredy J; Podjarny AD
Bioorg Med Chem Lett; 2009 Apr; 19(7):2006-8. PubMed ID: 19250825
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
Van Zandt MC; Jones ML; Gunn DE; Geraci LS; Jones JH; Sawicki DR; Sredy J; Jacot JL; Dicioccio AT; Petrova T; Mitschler A; Podjarny AD
J Med Chem; 2005 May; 48(9):3141-52. PubMed ID: 15857120
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications.
Van Zandt MC; Sibley EO; McCann EE; Combs KJ; Flam B; Sawicki DR; Sabetta A; Carrington A; Sredy J; Howard E; Mitschler A; Podjarny AD
Bioorg Med Chem; 2004 Nov; 12(21):5661-75. PubMed ID: 15465344
[TBL] [Abstract][Full Text] [Related]
4. Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids.
Kotani T; Nagaki Y; Ishii A; Konishi Y; Yago H; Suehiro S; Okukado N; Okamoto K
J Med Chem; 1997 Feb; 40(5):684-94. PubMed ID: 9057855
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, activity, and molecular modeling of new 2, 4-dioxo-5-(naphthylmethylene)-3-thiazolidineacetic acids and 2-thioxo analogues as potent aldose reductase inhibitors.
Fresneau P; Cussac M; Morand JM; Szymonski B; Tranqui D; Leclerc G
J Med Chem; 1998 Nov; 41(24):4706-15. PubMed ID: 9822541
[TBL] [Abstract][Full Text] [Related]
6. Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
Da Settimo F; Primofiore G; Da Settimo A; La Motta C; Simorini F; Novellino E; Greco G; Lavecchia A; Boldrini E
J Med Chem; 2003 Apr; 46(8):1419-28. PubMed ID: 12672241
[TBL] [Abstract][Full Text] [Related]
7. Highly selective aldose reductase inhibitors. 1. 3-(Arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic acids.
Ishii A; Kotani T; Nagaki Y; Shibayama Y; Toyomaki Y; Okukado N; Ienaga K; Okamoto K
J Med Chem; 1996 Apr; 39(9):1924-7. PubMed ID: 8627616
[TBL] [Abstract][Full Text] [Related]
8. Substituted pyrrol-1-ylacetic acids that combine aldose reductase enzyme inhibitory activity and ability to prevent the nonenzymatic irreversible modification of proteins from monosaccharides.
Nicolaou I; Demopoulos VJ
J Med Chem; 2003 Jan; 46(3):417-26. PubMed ID: 12540241
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of novel aldose reductase inhibitors: Effects on lens protein kinase Cgamma.
Lewis S; Karrer J; Saleh S; Chan X; Tan Z; Hua D; McGill J; Pang YP; Fenwick B; Brightman A; Takemoto D
Mol Vis; 2001 Jul; 7():164-71. PubMed ID: 11483892
[TBL] [Abstract][Full Text] [Related]
10. Naphtho[1,2-d]isothiazole acetic acid derivatives as a novel class of selective aldose reductase inhibitors.
Da Settimo F; Primofiore G; La Motta C; Sartini S; Taliani S; Simorini F; Marini AM; Lavecchia A; Novellino E; Boldrini E
J Med Chem; 2005 Nov; 48(22):6897-907. PubMed ID: 16250648
[TBL] [Abstract][Full Text] [Related]
11. On-bead combinatorial techniques for the identification of selective aldose reductase inhibitors.
Robins LI; Dixon SM; Wilson DK; Kurth MJ
Bioorg Med Chem; 2006 Dec; 14(23):7728-35. PubMed ID: 16931029
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of [5-(4-pyrrol-1-yl-benzoyl)-1 H-pyrrol-2-yl)]-acetic acid and in vitro study of its inhibitory activity on aldose reductase enzyme and on protein glycation.
Anagnostou C; Nicolaou I; Demopoulos VJ
Pharmazie; 2002 Jul; 57(7):435-7. PubMed ID: 12168519
[TBL] [Abstract][Full Text] [Related]
13. Exploring structural requirements for aldose-reductase inhibition by 2,4-dioxo-5-(naphth-2-ylmethylene)-3-thiazolidinyl acetic acids and 2-thioxo analogues: Fujita-Ban and Hansch approach.
Soni LK; Kaskhedikar SG
Arch Pharm (Weinheim); 2006 Jun; 339(6):327-31. PubMed ID: 16622827
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and aldose reductase inhibitory activities of novel thienocinnolinone derivatives.
Pau A; Asproni B; Boatto G; Grella GE; De Caprariis P; Costantino L; Pinna GA
Eur J Pharm Sci; 2004 Mar; 21(4):545-52. PubMed ID: 14998586
[TBL] [Abstract][Full Text] [Related]
15. In vitro inhibition of lens aldose reductase by (2-benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole-8-yl)-acetic acid in enzyme preparations isolated from diabetic rats.
Djoubissie PO; Snirc V; Sotnikova R; Zurova J; Kyselova Z; Skalska S; Gajdosik A; Javorkova V; Vlkovicova J; Vrbjar N; Stefek M
Gen Physiol Biophys; 2006 Dec; 25(4):415-25. PubMed ID: 17356233
[TBL] [Abstract][Full Text] [Related]
16. Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor.
Courtney SM; Hay PA; Buck RT; Colville CS; Phillips DJ; Scopes DI; Pollard FC; Page MJ; Bennett JM; Hircock ML; McKenzie EA; Bhaman M; Felix R; Stubberfield CR; Turner PR
Bioorg Med Chem Lett; 2005 May; 15(9):2295-9. PubMed ID: 15837312
[TBL] [Abstract][Full Text] [Related]
17. Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners.
Negoro T; Murata M; Ueda S; Fujitani B; Ono Y; Kuromiya A; Komiya M; Suzuki K; Matsumoto J
J Med Chem; 1998 Oct; 41(21):4118-29. PubMed ID: 9767647
[TBL] [Abstract][Full Text] [Related]
18. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations.
Sotriffer CA; Krämer O; Klebe G
Proteins; 2004 Jul; 56(1):52-66. PubMed ID: 15162486
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of novel benzoic acid derivatives with benzothiazolyl subunit and evaluation as aldose reductase inhibitors.
Rakowitz D; Hennig B; Nagano M; Steger S; Costantino L; Matuszczak B
Arch Pharm (Weinheim); 2005 Sep; 338(9):411-8. PubMed ID: 16143954
[TBL] [Abstract][Full Text] [Related]
20. How reliable are current docking approaches for structure-based drug design? Lessons from aldose reductase.
Zentgraf M; Steuber H; Koch C; La Motta C; Sartini S; Sotriffer CA; Klebe G
Angew Chem Int Ed Engl; 2007; 46(19):3575-8. PubMed ID: 17394265
[No Abstract] [Full Text] [Related]
[Next] [New Search]
